공시 • Apr 21
2invest AG, Annual General Meeting, May 27, 2026 2invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time. New Risk • Apr 16
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m). 공시 • Mar 04
2invest AG, Annual General Meeting, Apr 11, 2025 2invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time. New Risk • Feb 21
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m). 공시 • May 08
2invest AG, Annual General Meeting, Jun 12, 2024 2invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time. New Risk • Mar 04
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€2.4m revenue, or US$2.7m). Market cap is less than US$100m (€45.4m market cap, or US$49.2m). New Risk • Jun 30
New major risk - Revenue and earnings growth Earnings have declined by 6.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.6% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€36.5m market cap, or US$39.7m). 공시 • Apr 15
2invest AG to Report Fiscal Year 2021 Results on Apr 19, 2022 2invest AG announced that they will report fiscal year 2021 results on Apr 19, 2022 Is New 90 Day High Low • Mar 15
New 90-day low: €11.52 The company is down 30% from a price of €16.43 on 15 December 2020. Underperformed the German market, which is up 10.0% over the last 90 days. Lagged the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Feb 22
New 90-day low: €1.40 The company is down 23% from its price of €1.82 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. Is New 90 Day High Low • Feb 04
New 90-day low: €1.60 The company is down 19% from its price of €1.98 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. 공시 • Dec 31
4basebio AG Announces Board Changes 4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas. 공시 • Dec 10
4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business. The Board of Directors of 4basebio AG (XTRA:4BSB) announced the spin-off of unknown majority stake in Genomics and DNA manufacturing business on August 17, 2020. A spin-off of Genomics and DNA manufacturing business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalized from the existing cash of 4basebio AG. The management board of 4basebio AG would join the Board of the spin-off and assume responsibility for the day to day operation of this organization. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The deal is subject to an ongoing legal and tax review. On November 3, 2020, the shareholders of 4basebio AG approved the transaction. The intention is to complete this core process by December 31, 2020.
4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business on December 8, 2020. 공시 • Dec 02
4basebio AG Announces Board Changes 4basebio AG announced that the previous member of the company's Supervisory Board, Mr. Hansjörg Plaggemars, resigned from his office as a member of the company's Supervisory Board by letter dated 29 November 2020. Mr. Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr. Plaggemars. In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting. Mr. Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth. Is New 90 Day High Low • Oct 22
New 90-day low: €1.95 The company is down 8.0% from its price of €2.12 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period. 